Targeting Metabo-Redox Network Vulnerability in Heart Failure and Sudden Death

针对心力衰竭和猝死中代谢氧化还原网络的脆弱性

• 批准号: 9522223
• 负责人: D Brian Foster
• 金额: $ 53.45万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-01 至 2022-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9522223
• 关键词: Action Potentials; Acute; Affect; Animal Model; Animals; Arrhythmia; Automobile Driving; CREB1 gene; Cardiac; Cavia; Cell Death; Chronic; Congestive Heart Failure; Coupling; Cross-Over Studies; Data; Defibrillators; Diagnosis; Disease; EFRAC; Electrophysiology (science); Event; Experimental Models; Extracellular Matrix; Family; Feedback; Functional disorder; Future; Gene Proteins; Genes; Genetic Transcription; Goals; Heart failure; Homeostasis; Human; Impairment; Implantable Defibrillators; Incidence; Inflammation; Intervention; Ion Channel; Long QT Syndrome; MAPK14 gene; MAPK8 gene; Mediating; Metabolic; Mitochondria; Mitogen-Activated Protein Kinases; Modeling; Muscle Cells; Nature; Nuclear; Organ; Outcome; Oxidation-Reduction; Oxidative Stress; Pathway Analysis; Pathway interactions; Patients; Phenotype; Phosphoproteins; Phosphorylation; Physiology; Post-Translational Protein Processing; Prevalence; Process; Property; Proteins; Proteome; Proteomics; Protocols documentation; Qualifying; Reactive Oxygen Species; Regulation; Risk; Second Messenger Systems; Signal Pathway; Signal Transduction; Sudden Death; Telemetry; Testing; Time; Work; antioxidant enzyme; design; effective therapy; experimental study; human disease; improved; in vivo; inhibitor/antagonist; insight; member; mortality; multiple omics; novel therapeutics; palliative; prevent; programs; response; sudden cardiac death; therapeutic target

Heart failure (HF) is increasing in prevalence and incidence in the US. Despite advances in treatment, mortality is ~50% within 5 years of diagnosis with half of those deaths from sudden cardiac death (SCD), many before ejection fraction has decreased to a qualifying level for an implantable defibrillator (EF35%). There are no effective therapies to specifically treat SCD, apart from a defibrillator, which is palliative, not preventive. The multifactorial nature of HF/SCD requires an approach that considers the integrative physiology of both the myocyte and the organ, and a suitable experimental model with features of the human disease. This project leverages a unique guinea pig HF model that recapitulates many important aspects described in human heart failure, including long QT syndrome, arrhythmogenic SCD, inflammation, extracellular matrix remodeling, impaired Ca2+ handling, metabolic remodeling, and oxidative stress. Employing cellular experiments with a multi-omic approach, our recent and new data provides a comprehensive understanding of the genes, proteins, and fluxes (ionic and metabolic) behind the pathophysiology of HF/SCD. We identified important control points involved in acute emergent events, such as impaired metabo-redox coupling leading to mitochondrial ROS (mROS) overload and SCD, and those that mediate chronic remodeling, characterized by suppression of metabolic and redox transcriptional programs, lowering the threshold for the acute events. Our exciting preliminary data shows that both SCD and HF can be prevented or reversed by treatment with the mitochondrial ROS (mROS) scavenger, mitoTEMPO. For the first time, we show that mROS drives chronic remodeling of the specific phosphoproteome and the expression proteome in HF, likely through mitogen-activated protein (MAP) kinase activation. Remarkably, the design of our mROS scavenger protocol allows us to discriminate between mechanisms impacting SCD risk versus those that alter contractile function. Thus, the overarching goal of this application is to determine which proteins are targets of acute regulation by mROS, contributing to SCD/arrhythmia risk, versus those that are implicated in chronic HF remodeling. We hypothesize that mROS acutely impairs Ca2+ handling and repolarization, but also acts as a second messenger causing negative HF outcomes by disrupting the normal coupling between cytosolic signals and the nuclear gene programs driving mitochondrial function, antioxidant enzymes, Ca2+ handling and action potential repolarization and that the chronic effects of mROS are transduced through activation of MAP kinases. Our aims are to 1) determine protein/phosphoprotein targets regulated by mROS that discriminate between high arrhythmia/SCD risk and the HF state, 2) determine the acute versus chronic contribution of mROS to the electrophysiologic, EC-coupling and ROS abnormalities underlying SCD and HF in myocytes and intact animals, and 3) determine which branch of the MAP kinase family mediates the mROS-dependent uncoupling between cytoplasmic signals and proteome remodeling.

心力衰竭（HF）在美国的患病率和发病率都在上升。尽管治疗取得了进步，但死亡率仍在上升